Document:

Exhibit 10.17

 

PERSONAL EMPLOYMENT AGREEMENT

BETWEEN NANOVIBRONIX AND Dr. JONA
ZUMERIS

 

AGREEMENT made as of March 1, 2008, between
NANO VIBRONIX (ISRAEL) LTD., an Israeli corporation, having an office at 47 Haatasia St. POB 515 Nesher, Israel 36603, (the "Company"),
which is a wholly-owned subsidiary of NANOVIBRONIX Inc., a Delaware corporation with an office at 601 Chestnut Street, Cedarhurst,
NY 11516, and Dr. Jona Zumeris (the "Employee").

 

 

WHEREAS, the Company desires to engage
the Employee in the position described in Exhibit A, and the Employee represent that he/she has the requisite skill and knowledge
to serve as such.

 

NOW, THEREFORE, in consideration of the
premises and of the mutual promises, representations and covenants herein contained, the parties hereto agree as follows:

 

1. EMPLOYMENT AND DUTIES

 

1.1 The Company hereby appoints the Employee
to act in the position described in Exhibit A. The Employee shall report regularly to the CEO of the Company with respect to Employee's
activities.

 

1.2 During the term of Employment hereunder,
Employee's employment shall be on a full time basis.

 

In the fulfillment
of his position in the Company, Employee shall devote his full attention and use his experience faithfully to the Company, shall
be available for work at all reasonable times, according to the Company’s policy and requirements, or in any work or other
engagement which might be in conflict with the interests of the Company, or might harm his work with the Company, unless he has
obtained prior written consent to such engagement from the Company. It is understood that Employee may undertake strictly volunteer
activities on behalf of recognized charity non-profit institutions, provided such activities do not harm or create conflicts of
any kind with his work with the Company.

 

However, employee may serve on Boards of
Directors of other companies as long as there is no conflict of interest.

 

1.3 It is agreed between the parties that
the duties and responsibilities of the Employee hereunder are of a managerial and administrative nature and require a special degree
of personal confidence, within the meaning of the Rest and Work Hours Law, 5711-1951 (the “Work Hours Law”). As such,
the provisions of the Work Hours Law shall not apply to this Agreement.

    	 

    	-2-

    

 

 

1.4 Employee shall perform Employee's duties
hereunder at the Company's facilities in Israel, but understands and agrees that Employee's position may involve extensive travel
abroad.

 

 

2. TERM OF EMPLOYMENT

 

2.1 The initial term of employment under
this Agreement shall begin on the date set forth in Exhibit A (the "Employment Date") and shall continue until it is
terminated as hereafter provided.

 

2.2 The Company may terminate this Agreement
and the employment relationship hereunder at its discretion at any time by giving the Employee 90 days prior written notice. The
Employee may terminate this Agreement and the employment relationship hereunder at Employee's discretion at any time by giving
the Company 90 days prior written notice.

 

2.3 During the period following notice
of termination by either party, this Agreement shall remain in full force and effect and there shall be no change in Employee's
position with the Company or any obligations hereunder, unless otherwise determined by the Company in a written notice to Employee,
and the Employee shall cooperate with the Company and use Employee's best efforts to assist the integration into the Company's
organization of the person or persons who will assume the Employee's responsibilities.

 

3. SALARY

 

3.1 The Company shall pay the Employee
a gross (“brutto”) monthly salary in the amount of New Israeli Shekels (“NIS”), set forth in Exhibit A.
(the "Salary"), which shall be paid 12 times annually (hereinafter "basic salary").

 

3.2 Payment of the Salary shall be made
no later then the 10th day of each calendar month after the month for which the salary is being made. The Company shall deduct
all required taxes and similar payments from the Salary and from all other payments made to the Employee.

 

3.3 The parties accept and agree that the
basic salary is an accurate and just consideration for the responsibility and assignments the Employee is about to undertake and
that an additional amount had been taken into account within the calculations of the basic salary and the other benefits Employee
may be granted, as a special remuneration for both, overtime and extra work beyond regular work time as well as his obligation
for non-competition. To remove any doubt, Employee waives and removes in advance any argument and/or claim, as he may have if at
all, for additional remuneration of any kind, due to overtime or extra work on weekends or on any irregular working times, or against
his obligation for non-competition.

 

    	 

    	-3-

    

 

4. INSURANCE AND SOCIAL
BENEFITS

 

4.1 The Company shall insure the Employee:
under an accepted "Manager's Insurance Scheme" or "Pension Fund" to be selected by the Employee; (hereinafter
referred to as the "Insurance Scheme") as follows: (i) the Company shall pay an amount equal to 5% of the Salary towards
a fund for insurance or pension, and shall deduct 5% from the Salary and pay such amount towards the Insurance Scheme for the Employee's
benefit; (ii) the Company shall also contribute 2.5% towards insurance for the event of loss of working ability (Ovdan Kosher Avoda)
in accordance with Company policy; and (iii) the Company shall pay an amount equal to 8.33% of the Salary towards a fund for severance
compensation.

 

4.2 The Company and the Employee shall
maintain an advanced study fund (Keren Hishtalmut Fund). The Company shall contribute to such Fund an amount equal to 7.5% of the
Salary, and the Employee shall contribute to such fund an amount equal to 2.5% of the Salary. Employee hereby instructs the Company
to transfer to such fund the amount of the Employee's and the Company's contribution from each monthly salary payment. For any
amounts contributed by the Company and the Employee in terms hereof which exceed the maximum permitted under the Law for tax purposes
(the “Excess Amounts”), the Company shall deposit such Excess Amounts into the advanced study fund, and the Employee
shall bear all taxes arising from the Excess Amounts. (It is further agreed and acknowledged by the Employee that any Excess Amounts
shall in no way be deemed to form part of the Salary and the Employee shall have no claim against the Company for any severance
pay or any social or other employment benefits arising from or based upon the Excess Amounts.)

 

4.3 Upon termination of this Agreement
by the Company or by the Employee, other than in circumstances justifying the non-payment of severance pay under applicable law,
the Company shall assign and transfer to the Employee, after Employee has met all of Employee's obligations including, but not
limited to, transfer all the information related to his job, to his replacement as the company shall assign, hereunder in connection
with such termination of employment, the ownership in the aforesaid Manager's Insurance Scheme and Keren Hishtalmut Fund. In the
event that this Agreement is terminated in circumstances justifying the non-payment of severance pay under applicable law, the
Company, in its absolute discretion, may retain its payments to the aforesaid Manager’s Insurance Scheme which were paid
according to sub-section 4.1(iii) above and release to the employee all other sums contributed by both parties to aforesaid Manager's
Insurance Scheme and Keren Hishtalmut Fund.

 

    	 

    	-4-

    

 

5. OTHER BENEFITS

 

5.1 To remove any doubt it is agreed and
accepted by the parties, that any bonus program, as much as shall prevail, if at all, cannot be considered an obligation of the
Company and the Company has no obligation or commitment to pay payments and/or bonuses and/or any benefit to Employee. Also it
is agreed and accepted by the parties, that the Company may, according to criteria of its sole discretion, pay or grant different
benefits and/or payments to certain Employees and not to others. Accordingly, Employee declares and confirms upon signing this
agreement, that he waives and removes in advance any argument and/or claim, as he may have if at all, for discrimination in bonuses
and/or other benefit payments that may be paid to certain employees or any employee and not paid to Employee.

 

5.2 The employee shall be entitled to be
reimbursed for Employee's necessary and actual business expenses in accordance with the Company’s policies, as the same shall
change from time to time.

 

5.3 Employee shall be entitled to that
number of vacation days per year set forth in Exhibit A. The employee will have to use at least 10 vacation days each year (out
of which, 5 days will have to be consecutive). The Company shall be entitled to direct use of the vacation days, at its discretion.
In the event that the demands of Employee's activities preclude or limit the ability of the Employee to actually use all or part
of such vacation in any year, the Employee shall be entitled to the balance of such vacation only in the next succeeding three
years or, if unable to take the balance in these next succeeding years, to receive an amount equal to the rate of Salary then applicable
to the vacation time not taken during such years, subject to applicable law.

 

5.4 Employee shall be entitled to receive
the statutory required “Recreation Pay” (Dmei Havra'a).

 

5.5         
The Company will provide a car (motor 2000) to the Employee (the “Car”), and will bear all of the fixed and
variable maintenance costs, including licenses, insurance, gas, repairs, etc., but excluding personal traffic summons and the like.
The Car will be leased by the Company, and will be returned to the Company by the Employee immediately upon the termination of
the relationship between the Company and the Employee. Under no circumstances shall the Employee have a lien on the Car. Use of
the Car at all times and payment of Early Return Fine shall be subject to the Company policies regarding the use of the Car, as
these shall be in effect from time to time.

 

5.6 Employee shall be entitled to full
sick leave payments.

 

    	 

    	-5-

    

 

6. STOCK OPTIONS.

 

The company shall grant the Employee options,
pending BOD resolution, at a discount of present share price as set forth in Exhibit A. They are subject to ESOP of the company.

Any future grant of stock options shall
be subject to such terms as the Board of Directors or its Committee in its sole discretion shall specify at the time of grant.

 

 

 

 

7.
TERMINATION

 

a.         This Agreement
may be terminated by either party with or without cause on the terms and conditions contained herein.

 

b. During such notice
period, the Company shall maintain the option to either employ Employee or renounce such employment, at any time during the notice
period

 

c.         Notwithstanding
the terms of the above subsection b, the Company may terminate this agreement for cause, without giving Employee any notice period
and with immediate effect, upon the occurrence of one or more of the causes as detailed in the following subsections. . In the
event of termination for such cause, Employee shall not be entitled to receive any distribution of the Insurance Program, or any
other severance benefit, except to the extent required by applicable law.

 

(i)         Employee has
committed any act of moral turpitude or dishonesty vis-à-vis the Company or any of its affiliates, customers, suppliers
or service providers, including but not limited to theft, fraud, embezzlement, breach of trust or fiduciary duty;

 

(ii)         Employee is
found by the Company to have been in willful neglect of his duty hereunder or Employee committed any material breach of this Agreement
other than a breach which is eligible for remedy and is remedied forthwith by Employee at the Company’s request;

 

(iii)         Employee has
been arrested or convicted for the commission of any crime involving an act of moral turpitude; or

 

(iv) Employee has violated
one or more of the restrictions set forth herein regarding confidentiality, inventions, work products and non-competition.         

    	 

    	-6-

    

(v)         Employee has
been involved in a conduct for which according to the Israeli labor law, employers are entitled to terminate work relations with
employees without the obligation to pay severance payments.

 

d.         In the event
Employee elects to terminate this Agreement, he shall give a written notice to the Company at least 30 days in advance.

 

e.         Upon termination
of this Agreement for any reason, Employee shall immediately return to the Company any equipment, including company car if same
supplied to him as part of work benefits, documentation and moneys advanced to him by the Company, and/or by any affiliate, customer
or supplier, as well as all other items, documents and materials as required hereunder. In the event Employee fails to do so, the
Company shall be entitled, as much as it is in compliance with Israeli labor laws, to withhold any salary payments, distribution
of the Insurance Program, or other severance benefit, if any, due hereunder until such time as Employee shall have complied fully
with the provisions of this subsection.

 

f.         In the event
that Employee owes the Company money at the time of the termination of this Agreement, the Company shall be entitled, as much as
it is in compliance with Israeli labor laws, to offset the amount owed by Employee from his last salary payment or any other payment
due to him prior to termination including any unreimbursed legitimate business expenses for which Employee is entitled to reimbursement
under this Agreement.

 

8. DUTIES.

 

Employee shall serve
as VP Research and shall be responsible for the overall Research and Technologies programs of all of the company products and other
functions as the Chief Executive Officer of the Company shall from time to time determine. The Employee shall comply, in the performance
of his duties with the policies of the Company.

 

9. REPRESENTATIONS
AND AGREEMENTS.

 

Employee represents
and warrants that he is free to enter into this Agreement and to perform the duties required hereunder, and that there are no employment
contracts or understandings, restrictive covenants or other restrictions, whether written or oral, preventing the performance of
his duties hereunder.

 

 

    	 

    	-7-

    

 

10. NON-DISCLOSURE
OF CONFIDENTIAL INFORMATION.

 

(a) Employee shall
not, during the term of this Agreement, or at any time following termination of this Agreement, directly or indirectly, disclose,
permit to be known or make accessible (other than as is required in the regular course of his duties or is required by law (in
which case Employee shall give the Company prior written notice of such required disclosure) or with the prior written consent
of the CEO), to any person, firm or corporation, any confidential information acquired by him during the course of, or as an incident
to, his employment. Such confidential information shall include, but shall not be limited to, proprietary technology, trade secrets,
patented processes, research and development data, know-how, market studies and forecasts, competitive analyses, pricing policies,
employee lists, personnel policies, the substance of agreements with customers and others, marketing or dealership arrangements,
servicing and training programs and arrangements, customer lists and any other documents embodying such confidential information.
This confidentiality obligation shall not apply to any confidential information which thereafter becomes publicly available other
than pursuant to a breach of this Section 10(a) by Executive.

 

(b) All information
and documents relating to the Company and its affiliates as hereinabove described (or other business affairs) shall be the exclusive
property of the Company, and Employee shall use commercially reasonable best efforts to prevent any publication or disclosure thereof.
Upon termination of Employee's employment with the Company, all documents, records, reports, writings and other similar documents
containing confidential information, including copies thereof, then in Employee's possession or control shall be returned and left
with the Company.

 

11. SPECIFIC PERFORMANCE.

 

Emplyee agrees that
if he breaches, or threatens to commit a breach of, any of the provisions of Section 9,10 (the "Restrictive Covenant"),
the Company shall have, in addition to, and not in lieu of, any other rights and remedies available to the Company under law and
in equity, the right to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction, it being agreed
that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that money
damages would not provide an adequate remedy to the Company. Notwithstanding the foregoing, nothing herein shall constitute a waiver
by Employee of his right to contest whether a breach or threatened breach of any Restrictive Covenant has occurred.

 

12. AMENDMENT OR ALTERATION.

 

No amendment or alteration
of the terms of this Agreement shall be valid unless made in writing and signed by both of the parties hereto.

 

13. GOVERNING LAW.

 

This Agreement shall be governed by the
laws of the State of Israel applicable to agreements made and to be performed therein.

 

 

    	 

    	-8-

    

14. SEVERABILITY.

 

The holding of any
provision of this Agreement to be invalid or unenforceable by a court of competent jurisdiction shall not affect any other provision
of this Agreement, which shall remain in full force and effect.

 

15. NOTICES.

 

Any notices required
or permitted to be given hereunder shall be sufficient if in writing, and if delivered by hand, or sent by certified mail, return
receipt requested, to the addresses set forth above or such other address as either party may from time to time designate in writing
to the other, and shall be deemed given as of 2 days after the date of the delivery or mailing.

 

16. WAIVER OR BREACH.

 

It is agreed that a
waiver by either party of a breach of any provision of this Agreement shall not operate, or be construed, as a waiver of any subsequent
breach by that same party.

 

17. ENTIRE AGREEMENT
AND BINDING EFFECT.

 

This Agreement contains
the entire agreement of the parties with respect to the subject matter hereof, shall be binding upon and inure to the benefit of
the parties hereto and their respective legal representatives, heirs, distributors, successors and assigns. Notwithstanding the
foregoing, all prior agreements between Employee and the Company relating to the confidentiality of information, trade secrets,
patents and stock options shall not be affected by this Agreement.

 

18. SURVIVAL.

 

The termination of
Employee's employment hereunder or the expiration of this Agreement shall not affect the enforceability of Sections, 10, and 11
hereof.

 

19. FURTHER ASSURANCES.

 

The parties agree to
execute and deliver all such further documents, agreements and instruments and take such other and further action as may be necessary
or appropriate to carry out the purposes and intent of this Agreement.

 

 

    	 

    	-9-

    

20. HEADINGS.

 

The Section headings
appearing in this Agreement are for the purposes of easy reference and shall not be considered a part of this Agreement or in any
way modify, demand or affect its provisions.

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the date and year first above written.

 

 

 

 

	 	NANO VIBRONIX (ISRAEL) LTD. 
	 	 	 
	 	By:	/s/ Harold Jacob	 
	 	 	 
	 	 	 
	 	/s/ Jona Zumeris	 
	 	Employee

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 

    	-10-

    

 

 

Exhibit A

 

To Personal Employment Agreement by and
between NanoVibronix Ltd.and the Employee whose name is set forth herein

 

	Name of Employee:	Dr. Jona Zumeris	 
	ID No. of Employee	303996086	 
	Address of Employee	16/8 Mor, Haifa	 
	Position in the Company	VP Technology	 
	Employment Date	1.9.2004	 
	Salary	19.500	 
	
        Options and Vesting Schedule:

         
	 	 
	Vacation Days Per Year:	15	 

 

 

	
        The Company:

         

        NANO VIBRONIX

         

        /s/ Harold Jacob

         

        By: HAROLD JACOB

         

        Title: CEO
	
        Employee: (print name): Dr. Jona Zumeris

         

        Signature:

         

        /s/ Jona ZumerisExhibit 10.7

 

NANO VIBRONIX, INC.

 

FORM OF SUBSCRIPTION AGREEMENT

SERIES B CONVERTIBLE PREFERRED STOCK

AND WARRANTS

 

SUBSCRIPTION AGREEMENT
(the “Agreement”) dated as of March ___, 2009 between Nano Vibronix, Inc., a Delaware corporation (the “Company”),
and the persons who execute this agreement as investors (collectively, the “Investors”).

 

WITNESSETH:

 

WHEREAS, the Company
desires to sell to the Investors, and the Investors desire to purchase, an aggregate of _______ shares of Series B Convertible
Preferred Stock, par value $.001 per share, of the Company (the “Shares”) with warrants, in substantially the
form attached hereto as Exhibit 1, exercisable to purchase an aggregate of ____ Shares at $17.25 per share, subject to adjustment
(the “Warrants”), all for an aggregate price of US$______.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, the parties hereto hereby agree as follows:

 

1.           Purchase
and Sale of Securities.

 

1.1.       Sale
and Issuance of Securities. The Company shall sell to the Investors and the Investors shall purchase from the Company, an aggregate
of (x) _____ Shares (the “Purchased Shares”) and (y) Warrants to purchase an aggregate of _____ shares of Common
Stock (the “Purchased Warrants” and, collectively with the Purchased Shares, the “Securities”),
for an aggregate purchase price of US$______.

 

1.2.       The
closing (the “Closing”) of the purchase and sale of the Securities hereunder shall take place within three
(3) business days of the date of this Agreement or such other date agreed to by the Company and the Investors (the “Closing
Date”). The Closing shall take place remotely by means of and concurrently with the electronic or facsimile exchange
of documents and signatures at the Company or at such location as is mutually acceptable to the Investors and the Company. At the
Closing:

 

(a)          each
Investor shall deliver to the Company by wire transfer as set forth below:

Mellon Bank Pittsburdgh, PA

ABA # :            
             043000261

FFC:                
               Merrill Lynch

Account # :                    
101-1730

Name on the account:     NanoVibronix
Inc

FFC:                                831-07B23

or such other
method of payment as the Company shall approve, an amount equal to the purchase price of the Securities purchased by such Investor
hereunder; and

 

    	 

    	 

    

  

(b)          the
Company shall issue and deliver to each Investor a stock certificate registered in the name of the Investor, representing the number
of Purchased Shares purchased by such Investor, and the number of Purchased Warrants purchased by such Investor; and

 

(c)          the
Company shall have obtained all requisite approvals and waivers of its Board of Directors and stockholders with respect to the
transactions described herein and the amendment and restatement of the Company’s certificate of incorporation in substantially
the form attached hereto as Exhibit 2 and shall have filed such certificate with the Secretary of State of the State of
Delaware.

 

2.           Representations
and Warranties of the Company. The Company hereby makes the following representations and warranties only:

 

2.1           The
Company (i) is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation,
(ii) has the corporate power and authority to own or lease its properties as and in the places where such business is conducted
and to carry on its business as conducted, and (iii) is duly qualified as a foreign corporation authorized to do business in every
jurisdiction where the failure to so qualify, individually or in the aggregate, would have a material adverse effect on the operations,
assets, liabilities, financial condition or business of the Company or its subsidiary (“Material Adverse Effect”).

 

2.2           The
subsidiary is duly incorporated and validly existing under the laws of its jurisdiction of incorporation and is qualified to do
business as a foreign corporation in each jurisdiction in which qualification is required, except where failure to so qualify would
not have a Material Adverse Effect.

 

2.3           As
of the date of this Agreement (assuming that the Restated Certificate has been filed) and as of the Closing, the Company (i) has
the requisite corporate power and authority to execute, deliver and perform this Agreement and the other documents set forth in
Section 1.2 above (“Transaction Documents”) and to incur the obligations herein and therein and (ii) has been authorized
by all necessary corporate action to execute, deliver and perform this Agreement and the other Transaction Documents and to consummate
the transactions contemplated hereby and thereby (the “Contemplated Transactions”).

 

2.4           Each
of this Agreement and the other Transaction Documents is a valid and binding obligation of the Company enforceable in accordance
with its terms except as limited by applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting the
enforcement of creditors’ rights and the availability of equitable remedies (regardless of whether such enforceability is
considered in a proceeding at law or equity).

 

2.5           
As of the date of this Agreement (assuming that the Restated Certificate has been filed) and as of the Closing, the issuance of
the Securities has been duly authorized by all necessary corporate action on the part of the Company and, when issued to, delivered
to, and paid for by the Investors in accordance with this Agreement, the Purchased Shares will be validly issued, fully paid and
non-assessable.

 

    	2

    	 

    

 

3.           Representations
and Warranties and Agreement of the Investors. Each Investor represents and warrants to the Company as follows:

 

3.1.        Authorization.
Each Investor (i) has full power and authority to execute, deliver and perform this Agreement and the other Transaction Documents
to which it is a party and to incur the obligations herein and therein and (ii) if applicable, has been authorized by all necessary
corporate action to execute, deliver and perform this Agreement and the other Transaction Documents and to consummate the Contemplated
Transactions. Each of this Agreement and the other Transaction Documents is a valid and binding obligation of Investor enforceable
in accordance with its terms, except as limited by applicable bankruptcy, reorganization, insolvency, moratorium or similar laws
affecting the enforcement of creditors’ rights and the availability of equitable remedies (regardless of whether such enforceability
is considered in a proceeding at law or equity).

 

3.2.        Securities
Laws Representations and Covenants of Investors.

 

(a)          This
Agreement is made with each Investor in reliance upon such Investor’s representation to the Company, which by such Investor’s
execution of this Agreement such Investor hereby confirms, that the Securities to be received by such Investor will be acquired
for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution
of any part thereof such that such Investor would constitute an “underwriter” under the Securities
Act of 1933, as amended (the “Securities Act”). The Investor has not granted any right to any other person to
acquire the Securities purchased by such Investor or the shares of the Company issuable upon the conversion or exercise of the
Securities (“Underlying Shares”) except as permitted by the Securities Act and other applicable securities laws.

 

(b)          Each
Investor understands and acknowledges that the offering of the Securities pursuant to this Agreement will not be registered under
the Securities Act or qualified under any other applicable securities laws on the grounds that the offering and sale of the Securities
are exempt from registration and qualification and that the Company’s reliance upon such exemption is predicated upon such
Investor’s representations set forth in this Agreement.

 

(c)          Each
Investor covenants that, unless the Purchased Shares, the Purchased Warrants, the Underlying Shares or any other shares of capital
stock of the Company received in respect of the foregoing have been registered pursuant to the Securities Act, such Investor will
not dispose of such securities unless and until such Investor shall have notified the Company of the proposed disposition and shall
have furnished the Company with an opinion of counsel reasonably satisfactory in form and substance to the Company and its counsel
to the effect that (i) such disposition will not require registration under the Securities Act and (ii) appropriate action
necessary for compliance with the Securities Act and any applicable state, local or foreign law has been taken. Therefore, such
Investor may be required to hold such securities for an indeterminate period.

 

    	3

    	 

    

 

(d)         Each
Investor further represents that such Investor (i) is able to fend for itself in the Contemplated Transactions; (ii) has such
knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of such Investor’s
prospective investment in the Securities; (iii)  has the ability to bear the economic risks of such Investor’s prospective
investment and can afford the complete loss of such investment; (iv)  has received all the information it considers necessary
or appropriate for deciding whether to purchase the Securities; (v)  has had access to officers of the Company and an opportunity
to ask questions of and receive satisfactory answers from such officers; (vi) qualifies as an “accredited investor”
as such term is defined under Rule 501 promulgated under the Securities Act; and (vi) in the case a corporation, a partnership,
a trust or other business entity, further represents by execution of this Agreement that it has not been organized for the purpose
of purchasing the Securities.

 

(e)         The
maximum liability of the Company under this Agreement to each Investor shall not exceed the purchase price paid by such Investor.
An Investor may not bring any claim arising out of this Agreement unless written notice of the claim shall have been given to the
Company no later than 3 months following of the date that the Company's financial statements for the period ending 31 December
2009 shall be made available.

 

(f)          Each Investor
shall provide all information and execute all documents that the Company shall deem necessary to prepare and file with the SEC
a Form D concerning the sale of the Securities.

 

3.3.         Legends.
All certificates for the Securities, and the Underlying Shares, and each certificate representing any shares of capital stock of
the Company received in respect of the foregoing, and each certificate for any such securities issued to subsequent transferees
of any such certificate shall bear the following legend:

 

			“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR
AN EXEMPTION THEREFROM UNDER SAID ACT.”

 

In addition, such certificates shall bear
any legend that, in the opinion of the Company’s counsel, is required under the other Transaction Documents or pursuant to
any state, local or foreign law governing the Securities or the Underlying Shares.

 

3.4.       Brokers or Finders. Each Investor
represents and warrants that neither the Company nor the Investor has incurred, directly or indirectly, as a result of any action
taken by the Investor, any liability for brokerage of finders’ fees or agents’ commissions or any similar charges in
connection with this Agreement.

 

    	4

    	 

    

 

3.5.      Buyout
Proposal.  If at any time (i) the Company receives from any third party (in which no stockholder has a significant
interest) a bona fide offer or proposal (a “Buyout Proposal”) to purchase all of the shares of the Company, or all
or substantially all of the assets of the Company, or to effect a merger or consolidation with the Company, which is conditioned
upon the sale of all shares of the Company to such third party or stockholder approval and (ii) the holders of shares representing
seventy five percent (75%) of the aggregate voting power of the Company approve the Buyout Proposal, then the Investors shall transfer
their stock in the Company to such third party or shall vote in favor of the proposed Buyout Proposal, as applicable.

 

4. Adjustments.

 

4.1  Definitions.

 

(a)      “Issuance
Conversion Event” shall mean an aggregate investment in the Company of $1,000,000 or more in which the Company shall have
issued shares in the Company or securities (including convertible debt) exercisable or convertible into shares in the Company at
a specific price per share, other than shares issued (i) to employees, directors or consultants pursuant to any equity compensation
plan or otherwise approved by the Company’s Board of Directors; (ii) by reason of a stock dividend, stock split, split-up
or other distribution of shares of Common Stock; (iii) to bona fide leasing companies, strategic partners, or major lenders; or
(iv) upon conversion or exercise of options, warrants or other convertible securities which are outstanding at the date of this
Agreement.

 

(b)      “Non-Qualifying
Issuance” shall mean an aggregate investment in the Company of less than $1,000,000 which is otherwise described in Section
4.1(a) above.

 

(c)      “Entity
Conversion Event” shall mean a reorganization, consolidation or merger of the Company into or with any other entity (other
than a transaction as a result of which the stockholders of the Company immediately prior to such transaction hold a majority of
the combined voting power of the surviving entity immediately after such transaction), the sale of all or substantially all of
the Company’s business assets, or the sale of all or substantially all of the shares in the Company.

 

(d)      “Conversion
Period” shall mean the period commencing immediately after the completion of the current round of investment and ending on
March 31, 2012.

 

4.2  The Securities
shall be subject to exchange and/or modification (as described below) upon the first to occur of the following events or election
during the Conversion Period:

 

(a)  In the event that
an Issuance Conversion Event shall occur during the Conversion Period, the Securities purchased under this Agreement and any Underlying
Shares purchased pursuant to the Warrants shall automatically be cancelled and shall represent solely the right to receive such
number of Issuance Conversion Event securities which would have been issued to such Investor pursuant to the terms of such Issuance
in consideration for the sum of: (1) the purchase price paid by the Investor hereunder, (2) any purchase price previously paid
in connection with any prior exercise of the Warrants, plus (3) simple interest at 8% per annum from the date of payment of such
amounts provided that   the purchase price for such Issuance Conversion Event securities shall be deemed reduced by
thirty (30%) percent.

 

    	5

    	 

    

 

(b) The Company shall
give the Investor written notice of each Non-Qualifying Issuance. Within 10 days of the Company’s notice, the Investor may
elect by written notice to the Company and the surrender of his Securities and any Underlying Shares purchased pursuant to the
Warrants to receive in exchange therefor such number of Non-Qualifying Issuance securities which would have been issued to him
in consideration for the sum of: (1) the purchase price paid by the Investor hereunder, plus (2) any purchase price previously
paid in connection with any prior exercise of the Warrants.

 

(c)  In the event that
an Entity Conversion Event shall occur during the Conversion Period, the Investor may elect to receive, in lieu of any distribution
due under the Amended and Restated Certificate of Incorporation and in cancellation of his Purchased Shares, proceeds (to the extent
available before any distributions are made to the holders of Series A Stock or Common Stock) equal to: (i) 130% of the purchase
price paid under this Agreement, plus (ii) an amount equal to simple interest on the purchase price at 8% per annum from the date
of payment.

 

4.3  In the event that
during the Conversion Period, a Conversion Event shall not have occurred and the Investor shall not have elected to exchange such
Investor’s Securities as set forth in Section 4.2(b) above, (a) the Investor shall be issued additional shares of Series
B Convertible Preferred Stock such that the Investor’s average purchase price for the Purchased Shares and the additional
shares issuable under this Section shall be $10.00 per share; and (b) the Purchased Warrants shall be amended so that the “Purchase
Price” therein shall be $10.00 per share and the aggregate number of Warrants increased accordingly. (Such $10.00 amount
shall be appropriately adjusted in the case of stock dividend, stock split or combination.)

 

5.           Miscellaneous.

 

5.1.       Entire
Agreement; Successors and Assigns. This Agreement (including all schedules and exhibits thereto) constitutes the entire contract
between the parties relative to the subject matter hereof and thereof. Any previous agreement among the parties with respect to
the sale of the Securities is superseded by this Agreement. The terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective executors, administrators, heirs, successors and assigns of the parties. Except as expressly
provided herein, nothing in this Agreement, expressed or implied, is intended to confer upon any party, other than the parties
hereto, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

5.2.       Governing
Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the
State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance
with the internal laws of the State of New York without regard to principles of conflicts of law. Each party hereby irrevocably
consents and submits to the jurisdiction of any New York State or United States Federal Court sitting in the State of New York,
County of New York, over any action or proceeding arising out of or relating to this Agreement and irrevocably consents to the
service of any and all process in any such action or proceeding by registered mail addressed to such party at its address shown
below. Each party further waives any objection to venue in New York and any objection to an action or proceeding in such state
and county on the basis of forum non-conveniens. Each party also waives any right to trial by jury.

 

    	6

    	 

    

 

5.3.       Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

5.4.       Headings.
The headings of the sections of this Agreement are for convenience and shall not by themselves determine the interpretation of
this Agreement.

 

5.5.      Notices. Any notice required or permitted
hereunder shall be given in writing and shall be deemed effectively given upon personal delivery and if a fax number has been provided,
upon delivery (with answerback confirmed), addressed to a party at its address and the fax number, if any, shown below or at such
other address and fax number as such party may designate by three days advance notice to the other party.

 

Any notice to the Investors shall be sent to the addresses set forth on the signature pages hereof.

 

	Any notice to the Company shall be sent to:	With a copy to:
	Nano Vibronix Inc.	 	 
	601 Chestnut Street	 	 
	Cedarhurst, NY 11516	 	Nano Vibronix, Inc.
	Attention: Dr. Harold Jacob	 	Fax:   +972 4 820 2794
	Fax: 516 569 6872	 	 

 

5.6.        Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be deemed prohibited or invalid under such applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, and such prohibition or invalidity shall not invalidate the remainder
of such provision or any other provision of this Agreement.

 

5.7.       Expenses.
Irrespective of whether the Closing is effected, the Company shall pay all costs and expenses that it incurs with respect to the
negotiation, execution, delivery and performance of this Agreement. Each Investor shall be responsible for all costs incurred by
it in connection with the negotiation, execution, delivery and performance of this Agreement including, but not limited to, legal
fees and expenses.

 

5.8        Amendments
and Waivers. Any provision of this Agreement may be amended and the observance of any provision of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the
Company and the holders of a majority of the aggregate then-outstanding Shares. Any amendment or waiver effected in accordance
with this Section shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding (including
the Underlying Shares or other securities into which such securities are convertible), each future holder of all such securities,
and the Company.

 

[REMAINDER OF PAGE INTENTIONALLY BLANK]

 

    	7

    	 

    

 

SIGNATURE PAGE

TO

NANO VIBRONIX INC.

SUBSCRIPTION AGREEMENT

  

IF the PURCHASER is an INDIVIDUAL, please
complete the following:

 

IN WITNESS WHEREOF, the undersigned has
executed this Agreement this __ day of ______________.

 

Amount of Subscription:

$_________ 

 

	Number of Purchased Shares:	 	Investor Name:
	 	 	 
	 	 	 
	 	 	Signature of Investor
	 	 	 
	 	 	 
	 	 	Social Security Number
	 	 	 
	 	 	 
	 	 	Address and Fax Number
	 	 	 
	 	 	 
	 	 	 
	ACCEPTED AND AGREED:	 	 
	 	 	 
	NANO VIBRONIX INC.	 	 
	 	 	 
	By:	 	 	 	 
	 	Name:	 	 
	 	Title:	 	 

 

	Dated:  	 	 	 

 

    	 

    	 

    

 

SIGNATURE PAGE

TO

NANO VIBRONIX, INC.

SUBSCRIPTION AGREEMENT

 

IF the INTERESTS will be held as JOINT TENANTS,
as TENANTS IN COMMON, or as COMMUNITY PROPERTY, please complete the following:

 

IN WITNESS WHEREOF, the undersigned has
executed this Agreement this __ day of ____________.

 

	Amount of Subscription:	 	 
	$__________________	 	Print Name of a Purchaser
	 	 	 
	Number of Purchased Shares:	 	 
	___________	 	Signature of a Purchaser
	 	 	 
	 	 	 
	 	 	Print Name of Spouse or Other Purchaser
	 	 	 
	 	 	 
	 	 	Signature of Spouse or Other Purchaser
	 	 	 
	 	 	 
	 	 	Social Security Number
	 	 	 
	 	 	 
	 	 	Address
	 	 	 
	 	 	 
	 	 	 
	ACCEPTED AND AGREED:	 	 
	 	 	 
	NANO VIBRONIX INC.	 	 
	 	 	 
	By:	 	 	 
	 	Name:	 	 
	 	Title:	 	 
	 	 	 
	Dated: ________________	 	 

 

    	 

    	 

    

 

SIGNATURE PAGE

TO

NANO VIBRONIX INC.

SUBSCRIPTION AGREEMENT

 

IF the PURCHASER is a PARTNERSHIP, CORPORATION,
TRUST or OTHER ENTITY, please complete the following:

 

IN WITNESS WHEREOF, the undersigned has
executed this Agreement this __ day of ______________.

 

	Amount of Subscription:	 	 
	$___________________	 	 
	 	 	 
	Number of Purchased Shares:	 	 
	_____________	 	 
	 	 	 
	 	 	Print Full Legal Name of Partnership,
	 	 	Company, Trust or Other Entity
	 	 	 
	 	 	By:	 
	 	 	 	     (Authorized Signatory)
	 	 	Name:	 
	 	 	Title:	 

 

	 	 	Address and Fax Number:	 
	 	 	 
	 	 	 

 

	 	Employer Identification Number: _________
	 	Date and State of Incorporation or Organization:______________________
	 	Date on which Taxable Year Ends:_________________________________

 

ACCEPTED AND AGREED:

	 
	NANO VIBRONIX INC.
	 
	By:	 	 
	Name:
	Title:
	
	Dated:

 

    	-2-

    	 

    

EXHIBIT 1

 

	Void after March 31, 2014	Warrant No. ________

 

This Warrant and any shares acquired
upon the exercise of this Warrant have not been registered under the Securities Act of 1933. This Warrant and such shares may not
be sold or transferred in the absence of such registration or an exemption therefrom under said Act. This Warrant and such shares
may not be transferred except upon the conditions specified in this Warrant, and no transfer of this Warrant or such shares shall
be valid or effective unless and until such conditions shall have been complied with.

 

NANO VIBRONIX, INC.

 

SERIES B PREFERRED STOCK PURCHASE WARRANT

 

Nano Vibronix, Inc. (the “Company”), having
its principal office at 601 Chestnut Street, Cedarhurst, NY 11516, hereby certifies that, for value received, _____________
(“Investor”), or assigns, is entitled, subject to the terms set forth below, to purchase from the Company at
any time on, or from time to time after, ________, 2009 and before 5:00 P.M., New York City time, on March 31, 2014, or as curtailed
in accordance with the terms hereof (the “Expiration Date”), ______________ fully paid and non-assessable shares of
Preferred Stock of the Company, at the Purchase Price per share of $17.25. The number and
character of such shares of Preferred Stock and the Purchase Price per share are subject to adjustment as provided herein.

 

This Warrant is subject to adjustment and modification in
accordance with the provisions of the Subscription Agreement dated as of _________, 2009 between the Company and the Investor,
et al (“Subscription Agreement”). 

 

As used herein, the following terms have the following respective
meanings:

 

“Preferred Stock” means the Series B Convertible
Preferred Stock, par value $.001 per share, of the Company.

 

“Exchange Act” means the Securities Exchange
Act of 1934 as the same shall be in effect at the time.

 

“Holder” means any record owner of this Warrant.

 

“Market Price” has the meaning set forth
in Section 2.4.

 

“Original Issue Date” means _______.

 

    	 

    	 

    

 

“Other Securities” refers to any stock (other
than Preferred Stock) and other securities of the Company or any other entity which the Holder of this Warrant at any time shall
be entitled to receive, or shall have received, upon the exercise of this Warrant, in lieu of or in addition to Preferred Stock,
or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Preferred Stock or Other
Securities pursuant to Section 5 or otherwise.

 

“Securities Act” means the Securities Act
of 1933 as the same shall be in effect at the time.

 

“Underlying Securities” means any Preferred
Stock or Other Securities issued or issuable upon exercise of this Warrant.

 

“Warrant” means, as applicable, this Warrant
or each right as set forth in this Warrant to purchase one share of Preferred Stock, as adjusted.

 

1.            Sale
or Exercise Without Registration. If, at the time of any exercise, transfer or surrender for exchange of a Warrant or of Underlying
Securities previously issued upon the exercise of Warrants, such Warrant or Underlying Securities shall not be registered under
the Securities Act, the Company may require, as a condition of allowing such exercise, transfer or exchange, that the Holder or
transferee of such Warrant or Underlying Securities, as the case may be, furnish to the Company an opinion of counsel, reasonably
satisfactory to the Company, to the effect that such exercise, transfer or exchange may be made without registration under the
Securities Act.

 

		2.	Exercise of Warrant.

 

			2.1.       Exercise in Full. Subject to the provisions hereof, this Warrant may be exercised in full by the Holder hereof
by surrender of this Warrant, with the form of subscription at the end hereof duly executed by such Holder, to the Company at its
principal office accompanied by payment, in cash or by certified or official bank check payable to the order of the Company, in
the amount obtained by multiplying the number of shares of Purchase Stock issuable upon exercise of this Warrant by the Purchase
Price per share, after giving effect to all adjustments through the date of exercise.

 

			2.2.      Partial Exercise. Subject to the provisions hereof,
this Warrant may be exercised in part by surrender of this Warrant in the manner and at the place provided in Section 3.1 except
that the amount payable by the Holder upon any partial exercise shall be the amount obtained by multiplying (a) the number of
shares of Preferred Stock (without giving effect to any adjustment therein) designated by the Holder in the subscription at the
end hereof, by (b) the Purchase Price per share. Upon any such partial exercise, the Company at its expense will forthwith issue
and deliver to or upon the order of the Holder hereof a new Warrant of like tenor, for the remaining number of shares of Preferred
Stock which may be purchased hereunder.

 

    	.2

    	 

    

 

			2.3.          Certain Exercises. If this Warrant is to be exercised
in connection with a registered public offering or sale of the Company, such exercise may, at the election of the Holder, be conditioned
on the consummation of the public offering or sale of the Company, in which case such exercise shall not be deemed effective until
the consummation of such transaction.

 

3.             Delivery
of Stock Certificates, etc., on Exercise. As soon as practicable after the exercise of this Warrant in full or in part, the
Company at its own expense (including the payment by it of any applicable issue taxes) will cause to be issued in the name of and
delivered to the Holder hereof, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct, a
certificate or certificates for the number of fully paid and non-assessable shares of Preferred Stock or Other Securities to which
such Holder shall be entitled upon such exercise, plus, in lieu of any fractional share to which such Holder would otherwise be
entitled, cash equal to such fraction multiplied by the then-current Market Price of one full share, together with any other stock
or other securities and property (including cash, where applicable) to which such Holder is entitled upon such exercise pursuant
to Section 4 or otherwise.

 

4.             Adjustment
for Dividends in Other Stock, Property, etc.; Reclassification, etc. In case at any time or from time to time after the Original
Issue Date, the holders of Preferred Stock (or, if applicable, Other Securities) shall have received, or (on or after the record
date fixed for the determination of stockholders eligible to receive) shall have become entitled to receive, without payment therefor

 

(a)     other or additional
stock or other securities or property (other than cash) by way of dividend, or

 

(b)     any cash paid or payable
(including, without limitation, by way of dividend), or

 

(c)     other or additional
stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, recapitalization, combination
of shares or similar corporate rearrangement,

 

then, and in each such case the Holder of this Warrant, upon
the exercise hereof as provided in Section 2, shall be entitled to receive the amount of stock and other securities and property
(including cash in the cases referred to in subdivisions (b) and (c) of this Section 4) which such Holder would hold on the date
of such exercise if on the Original Issue Date such Holder had been the Holder of record of the number of shares of Preferred Stock
called for on the face of this Warrant and had thereafter, during the period from the Original Issue Date to and including the
date of such exercise, retained such shares and all such other or additional stock and other securities and property (including
cash in the cases referred to in subdivisions (b) and (c) of this Section 4) receivable by such Holder as aforesaid during such
period, giving effect to all adjustments called for during such period by Section 5 hereof. If the number of shares of Preferred
Stock outstanding at any time after the date hereof is decreased by a combination or reverse stock split of the outstanding shares
of Common Stock, the Purchase Price per share shall be increased, and the number of shares of Preferred Stock purchasable under
this Warrant shall be decreased in proportion to such decrease in outstanding shares of Preferred Stock.

 

    	.3

    	 

    

  

5.     Reorganization,
Consolidation, Merger, etc. In case the Company after the Original Issue Date shall (a) effect a reorganization, (b) consolidate
with or merge into any other entity or (c) transfer all or substantially all of its properties or assets to any other entity under
any plan or arrangement contemplating the dissolution of the Company, then, in each such case, the Warrant shall be terminated
upon such consummation or dissolution.

 

6.     Further
Assurances. The Company will take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and non-assessable shares of stock upon the exercise of all Warrants from time to time outstanding.

 

7.     Officer's
Certificate as to Adjustments. In each case of any adjustment or readjustment in the shares of Preferred Stock (or Other Securities)
issuable upon the exercise of the Warrants, the Company will issue a certificate setting forth such adjustment or readjustment
and the basis therefor .

 

8.     Notices
of Record Date, etc. In the event of

 

(a)      any taking by the Company
of a record of its stockholders for the purpose of determining the stockholders thereof who are entitled to receive any dividend
or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other
securities or property, or to receive any other right, or for the purpose of determining stockholders who are entitled to vote
in connection with any proposed capital reorganization of the Company, any reclassification or recapitalization of the capital
stock of the Company or any transfer of all or substantially all the assets of the Company to or consolidation or merger of the
Company with or into any other person, or

 

(b)      any voluntary or involuntary
dissolution, liquidation or winding-up of the Company, or

 

  (c)          any proposed issue or grant by the Company of any Common Stock, or any other securities, or any right or option to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities (other than the issue of Common Stock on the exercise of the Warrants),

 

then and in each such event the Company will mail or cause to
be mailed to each Holder of a Warrant a notice specifying (i) the date on which any such record is to be taken for the purpose
of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, (ii) the
date on which any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation
or winding-up is to take place, and the time, if any, as of which the Holders of record of Underlying Securities shall be entitled
to exchange their shares of Underlying Securities for securities or other property deliverable upon such reorganization, reclassification,
recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up and (iii) the amount and character of
any stock or other securities, or rights or options with respect thereto, proposed to be issued or granted, the date of such proposed
issue or grant and the persons or class of persons to whom such proposed issue or grant and the persons or class of persons to
whom such proposed issue or grant is to be offered or made. Such notice shall be given at least 10 days prior to the date therein
specified.

 

    	.4

    	 

    

  

9.          Reservation
of Stock, etc., Issuable on Exercise of Warrants. The Company will at all times reserve and keep available, solely for issuance
and delivery upon the exercise of the Warrants, all shares of Preferred Stock (or Other Securities) from time to time issuable
upon the exercise of the Warrants.

 

10.         Notices,
etc. All notices and other communications from the Company to the Holder of this Warrant shall be delivered by fax or courier,
at such address as may have been furnished to the Company in writing by such Holder, or, until an address is so furnished, to and
at the address of the last Holder of this Warrant who has so furnished an address to the Company.

 

11.         Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
Company and the Holder or as otherwise provided in the Subscription Agreement. This Warrant shall be governed by and construed
and enforced in accordance with the General Corporation Law of the State of Delaware without regard to principles of conflicts
of law. Each party hereby irrevocably consents and submits to the jurisdiction of any New York State or United States Federal Court
sitting in the State of New York, County of New York, over any action or proceeding arising out of or relating to this Agreement
and irrevocably consents to the service of any and all process in any such action or proceeding by registered mail addressed to
such party at its address specified herein (or as otherwise noticed to the other party). Each party further waives any objection
to venue in New York and any objection to an action or proceeding in such state and county on the basis of forum non conveniens.
Each party also waives any right to trial by jury.

 

	Dated: __________ __, 2009	NANO VIBRONIX, INC.
	 	 	 	By:	 
	 	 	 	Name:	 
	Attest:	 		Title:	 

 

    	.5

    	 

    

 

FORM OF SUBSCRIPTION

 

(To be signed only upon exercise of Warrant)

 

To: NANO VIBRONIX, INC.

 

The undersigned, the Holder of the within
Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder,
_________ shares of Preferred Stock of Nano Vibronix, Inc., and herewith makes payment therefor of $ * and requests that
the certificates for such shares be issued in the name of, and delivered to, ___________________, whose address is _______________________.

Dated:

 

	 	 
	 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
	 	 
	 	
	 	(Address)

 

		*	Insert here the number of shares called for on the face of the Warrant (or, in the case of a partial exercise, the portion
thereof as to which the Warrant is being exercised), in either case without making any adjustment for additional Preferred Stock
or any other stock or other securities or property or cash which, pursuant to the adjustment provisions of the Warrant, may be
deliverable upon exercise.

 

    	.6

    	 

    

EXHIBIT 2

 

 

AMENDED AND RESTATED

 

CERTIFICATE OF INCORPORATION

 

OF

 

NANO VIBRONIX, INC.

 

Nano Vibronix, Inc.
(the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law
of the State of Delaware (the “GCL”), does hereby certify that:

 

1.           The
name of the corporation is Nano Vibronix, Inc.

 

2.           The
original Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware on October 20, 2003.

 

3.           This
Amended and Restated Certificate of Incorporation, which amends and restates the Corporation’s Certificate of Incorporation
in its entirety, has been duly adopted with the provisions of Sections 242 and 245 of the GCL, and the stockholders of the Corporation
have given their written consent in accordance with the provisions of Section 228 of the General Corporation Law of the State of
Delaware. The provisions of the Amended and Restated Certificate of Incorporation are as follows:

 

ARTICLE I

Name

 

The name of this corporation
is Nano Vibronix, Inc. (the “Corporation”).

 

ARTICLE II

Registered Office

 

The registered office
in the State of Delaware is located at 1313 Market Street, Suite 5100, in the City of Wilmington 19801, County of New Castle, and
its registered agent at such address is PHS Corporate Services, Inc.

 

    	 

    	 

    

 

ARTICLE III

Purpose

 

The purpose of the Corporation
is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State
of Delaware (the “GCL”).

 

ARTICLE IV

Authorized Capital

 

The Corporation is authorized
to issue two classes of capital stock to be designated, respectively, “Common Stock” and “Preferred Stock”.
The total number of shares that the Corporation is authorized to issue is three million four hundred thousand (3,400,000). Two
million four hundred thousand (2,400,000) shares shall be Common Stock, par value $0.001 per share, and one million (1,000,000)
shares shall be Preferred Stock, par value $0.001 per share.

 

Section 4A.          Common
Stock.

 

4A.1.     General.
Subject to the powers, preferences and rights of any Preferred Stock, including any series thereof, having any preference priority
over, or rights superior to, the Common Stock and except as otherwise provided by law and this Article, the holders of the Common
Stock shall have and possess all powers and voting and other rights pertaining to the stock of the corporation and each share of
Common Stock shall be entitled to one vote. Except as otherwise provided by the Delaware General Corporation Law or this Third
Amended and Restated Certificate of Incorporation, the holders of record of Common Stock shall share ratably in all dividends payable
in cash, stock or otherwise and other distributions, whether in respect of liquidation or dissolution (voluntary or involuntary)
or otherwise.

 

4A.2.     Voting.
The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders. There
shall be no cumulative voting.

 

4A.3      Number.
The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then
outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective
of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.

 

    	 

    	 

    

 

4A.4      Dividends.
Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board
of Directors and subject to any preferential dividend rights of any then outstanding Preferred Stock.

 

4A.5      Liquidation.
Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled
to receive ratably in all assets of the Corporation available for distribution to its stockholders, subject to any preferential
rights of any then outstanding Preferred Stock.

 

Section 4B.          Of
the Preferred Stock, seven hundred thousand (700,000) shares shall be designated the Series A Participating Convertible Preferred
Stock (the “Series A Stock”) and three hundred thousand (300,000) shares shall be designated the Series B Participating
Convertible Preferred Stock (the “Series B Stock”). Capitalized terms not otherwise defined have the meanings
set forth in Section 4.6 below. The rights, preferences, privileges and restrictions, and the number of shares constituting each
such series (the “Series”) and the designation of such series, are set forth as follows:

 

4B.1.      Number
and Designation. Any increase or decrease in the number of authorized shares of the Series shall be effectuated by filing an
amendment to this Fourth Amended and Restated Certificate of Incorporation that has been duly adopted by the Board of Directors
of the Corporation and approved by the stockholders of the Corporation pursuant to the provisions of the GCL and that states that
such increase or reduction has been so authorized.

 

4B.2.      Dividends.
When and as any dividend or distribution is declared or paid by the Corporation on Common Stock, whether payable in cash, property,
securities or rights to acquire securities, the Series A Holders and Series B Holders will be entitled to participate with the
holders of Common Stock in such dividend or distribution as set forth in this Section 4B.2. At the time such dividend or distribution
is payable to the holders of Common Stock, the Corporation will pay to each Series A Holder and Series B Holder such holder’s
share of such dividend or distribution equal to the amount of the dividend or distribution per share of Common Stock payable at
such time multiplied by the aggregate number of shares of Common Stock then obtainable upon conversion of such holder’s Preferred
Stock.

 

    	 

    	 

    

 

4B.3.      Voting
Rights.

 

A.           Generally.
Except as otherwise required by law or as set forth herein, the Series A Holders and Series B Holders shall be entitled to notice
of any shareholders’ meeting and to vote together with the Common Stock, and not as a separate class (except as specifically
provided herein or otherwise required by law), upon any matter submitted for approval by the holders of Common Stock on the following
basis: the Series A Holders and Series B Holder shall have that number of votes equal to the aggregate number of shares of Common
Stock into which their outstanding Preferred Stock is then convertible.

 

B.           Series
A Directors. Until the earlier to occur of (i) a QIPO or (ii) the point at which the equity beneficially owned by the Investors
constitutes less than five percent (5%) of the fully-diluted equity of the Corporation, the 2005 Investors shall have the exclusive
right to elect one member of the Board of Directors of the Corporation (the “2005 Series A Director”), who shall
also be appointed to the Compensation Committee of the Board of Directors. Until the earlier to occur of (i) a QIPO or (ii) the
point at which the equity beneficially owned by the 2007 Investors constitutes less than five percent (5%) of the fully-diluted
equity of the Corporation, Ludgate Investments Limited shall have the exclusive right to elect one member of the Board of Directors
of the Corporation (the “2007 Series A Director”). The manner of election of the remaining members of the Board
of Directors of the Corporation shall be as set forth in the Bylaws of the Corporation.

 

C.           In
addition to any other rights provided by law, so long as any Series A Stock is outstanding but only until the earlier to occur
of (x) a QIPO or (y) the point at which the equity beneficially owned by each of the 2005 Investors and the 2007 Investors constitutes
less than five percent (5%) of the fully-diluted equity of the Corporation (except with respect to clause (i) below, which shall
remain in place so long as any Series A Stock is outstanding), the Corporation, without first obtaining the affirmative vote or
written consent of the holders of not less than a majority of the outstanding shares of the Series A Stock, will not:

 

(i)          amend
or repeal any provision of, or add any provision to, the Corporation’s Certificate of Incorporation, as amended or By-Laws
if such action would alter adversely the liquidation preferences of, or other priorities, rights or privileges provided for the
benefit of, the Series A Stock; or

 

    	 

    	 

    

 

(ii)         authorize
or issue shares of any class or series of stock (other than the Series A Stock) having any preference or priority as to dividends,
voting or liquidation or other rights superior to, or pari passu with, any such preference, priority, right or privilege
of the Series A Stock, or authorize or issue shares of stock of any class or any bonds, debentures, notes or other obligations
convertible into or exchangeable for, or having option rights to purchase, any shares of stock of the Corporation having any preference
or priority as to dividends, voting or liquidation or other rights superior to any such priority, right or privilege of the Series
A Stock;

 

(iii)        reclassify
any class or series of stock junior to the Series A Stock into stock senior to the Series A Stock with respect to any preference,
priority, right or privilege;

 

(iv)        repurchase
or redeem any equity securities of the Corporation; or

 

(v)         increase
the number of members of the Corporation’s Board of Directors to more than five members, except in connection with the issuance
of equity securities of the Corporation to investors who purchase a minimum of fifteen percent (15%) of the then-current fully
diluted equity of the Corporation.

 

4B.4.      Preference
Upon Liquidation.

 

A.           Upon
any liquidation, dissolution or winding up of the Corporation, (i) first, each Series B Holder will be entitled to be paid, before
any distribution or payment is made upon any other securities of the Corporation, an amount in cash equal to the aggregate Liquidation
Value of all shares of Series B Stock held by such holder; (ii) second, each Series A Holder will be entitled to be paid, before
any distribution or payment is made upon any Junior Securities of the Corporation, an amount in cash equal to the aggregate Liquidation
Value of all shares of Series A Stock held by such holder; (iii) thereafter, each Series A Holder and Series B Holder shall participate
in any distribution or payment on a pro rata basis with all Junior Securities and such shares shall thereafter have only the rights
of Common Stock as if such holder’s Preferred Stock had been converted into Common Stock pursuant to Section 4B.5(A).

 

    	 

    	 

    

 

B.           Notwithstanding
Section 4B.5B(ii) below, the reorganization, consolidation or the merger of the Corporation into or with any other corporation(s)
or other entity(ies) (other than a transaction as a result of which the stockholders of the Corporation immediately prior to such
transaction hold a majority of the combined voting power of the surviving entity immediately after such transaction) (a “Reorganization”),
the sale, lease, licensing, exchange or other transfer by the Corporation of all or more than 50% of the Corporation’s business
assets or the commencement by the Corporation of a voluntary case under the United States bankruptcy laws or any applicable bankruptcy,
insolvency or similar law of any other country, or consent to the entry of an order for relief in an involuntary case under any
such law or to the appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or other similar official)
of the Corporation or of or more than 50% of the Corporation’s business assets, or the making of an assignment for the benefit
of its creditors, or an admission in writing of its inability to pay its debts generally as they become due (any of such actions
or events, a “Material Event”), will be deemed to be a liquidation, dissolution or winding up of the Corporation
within the meaning of this Section 4B.4. Notwithstanding the foregoing, any Series A Holder [or Series B Holder] may elect, in
such holder’s sole discretion, upon written notice to the Corporation not less than three (3) days before any such Reorganization,
for such Reorganization of the Corporation not to be deemed to be a liquidation, dissolution or winding up of the Corporation within
the meaning of this Section 4B.4 with respect to such holder’s shares.

 

4B.5.      Conversion
into Conversion Stock

 

A.           Conversion.

 

(i)           Mandatory
Conversion.

 

(a)          Upon
QIPO. All of the outstanding shares of Series A Stock and Series B Stock will be automatically converted into the number of
shares of Conversion Stock calculated in accordance with the provisions of Section 4.5A(iii) hereof upon the closing of the QIPO.
Written notice of such mandatory conversion shall be delivered to all holders of Preferred Stock as soon as reasonably possible
following the entry into definitive agreements for the consummation of the QIPO.

 

(b)          Upon
Call of Required Holders. The Required Holders of the Series A Stock or Series B Stock may, upon at least thirty (30) days
notice to the Corporation, cause each outstanding share of Series A Stock or Series B Stock, respectively, to be called for conversion
into shares of Common Stock at the then effective Conversion Price (a “Required Conversion”). Such notice shall
state the requested date of conversion. The Corporation shall give notice of any Required Conversion, at least fifteen (15) days
prior to the requested date of conversion, by certified or registered mail (return receipt requested), postage prepaid, to each
of the Series A Holders or Series B Holders (other than the Required Holders who have given a notice of conversion). Such notice
shall be addressed to each such Series A Holder or Series B Holder at the address as it appears on the stock transfer books of
the Corporation and shall specify the date of conversion and the number of shares requested to be converted.

 

    	 

    	 

    

 

(ii)          Optional
Conversion. A Series A Holder or Series B Holder shall at any time have the right to convert any or all of its shares of Preferred
Stock into the number of shares of Conversion Stock calculated in accordance with the provisions of Section 4B.5A(iii) hereof.

 

(iii)         Conversion
Ratio. Upon conversion of any or all shares of Preferred Stock pursuant to this Section 4B.5A, the Holder shall be entitled
to receive the number of shares of Conversion Stock equal to the product of (a) the number of shares of Preferred Stock being converted
and (b) a fraction, the numerator of which shall be equal to the Series Issuance Price (as hereafter defined), and the denominator
of which shall be equal to the then-applicable Conversion Price (as adjusted, if applicable, pursuant to the provisions of Section
4B.5B hereof).

 

(iv)         As
soon as possible after a conversion has been effected, the Corporation will deliver to the converting holder:

 

(a)          a
certificate or certificates representing the number of shares of Conversion Stock issuable by reason of such conversion in such
name or names and such denomination or denominations as the converting holder has specified; and

 

    	 

    	 

    

 

(b)          a
certificate representing any shares of Series A Stock which were represented by the certificate or certificates delivered to the
Corporation in connection with such conversion but which were not converted.

 

(v)          Fractional
Shares. No fractional shares of Conversion Stock shall be issued upon any conversion. In lieu of any fractional share of Conversion
Stock that would have been issuable upon any conversion, the Corporation will pay the holder of the Conversion Stock the Fair Market
Value of such fractional share.

 

(vi)         Conversion
Fees. The issuance of certificates for shares of Conversion Stock upon conversion of Preferred Stock will be made without charge.

 

(vii)        Books
of the Corporation. The Corporation will not close its books against the transfer of Preferred Stock or Conversion Stock issued
or issuable upon conversion of Preferred Stock in any manner which interferes with the conversion of Preferred Stock.

 

B.           Adjustment
of Conversion Price. In order to prevent dilution of the conversion rights granted under this Section, the Conversion Price
will be subject to adjustment from time to time pursuant to this Section 4B.5B.

 

(i)           Subdivision
or Combination of Common Stock; Dissolution.

 

(a)          If
the Corporation at any time or from time to time following the Original Issue Date subdivides (by any reclassification, stock split,
stock dividend or otherwise) its outstanding shares of Common Stock into a greater number of shares (without a corresponding change
to the Series A Stock), the Conversion Price in effect immediately prior to such subdivision will, concurrently with the effectiveness
of such subdivision, be proportionately reduced, and if the Corporation at any time combines (by reclassification, reverse stock
split or otherwise) its outstanding shares of Common Stock into a smaller number of shares (without a corresponding change to its
Preferred Stock), the Conversion Price in effect immediately prior to such combination will, concurrently with the effectiveness
of such combination, be proportionately increased. In the event of any such reclassification, stock split, stock dividend or subdivision,
each Series A Holder and Series B Holder shall have the right thereafter to convert such stock into the kind and amount of
stock and other securities and property receivable upon such recapitalization, reclassification or other change by holders of the
maximum number of shares of Common Stock into which such shares of Preferred Stock could have been converted immediately prior
to such recapitalization, reclassification, stock split, subdivision or other change, all subject to further adjustment as provided
herein or as provided by the terms of such other securities or property.

 

    	 

    	 

    

 

(b)          In
the event of a judicial or non-judicial dissolution of the Corporation, the conversion rights and privileges of the Series A Holders
and Series B Holders shall terminate on a date, as fixed by the Board of Directors of the Corporation, not more than 30 days and
not less than 3 days before the date of such dissolution; provided that the Series A Holders and Series B Holders receive at least
45 days prior notice of such dissolution setting forth in detail the material terms of dissolution.

 

(ii)          Reorganizations,
Mergers or Consolidations. If at any time or from time to time after the Original Issue Date, there is a capital reorganization
of the Common Stock (without a corresponding change to the Preferred Stock) or the merger or consolidation of the Corporation with
or into another corporation or another entity or person, as a part of such capital reorganization, merger or consolidation, provision
shall be made so that the Preferred Stock Holders shall thereafter be entitled to receive, upon conversion of the Preferred Stock
Stock, the number of shares of stock or other securities or property to which a holder of the number of shares of Common Stock
deliverable upon conversion would have been entitled on such capital reorganization, merger or consolidation, subject to adjustment
in respect of such stock or securities by the terms thereof. In any such case, appropriate adjustment shall be made in the application
of the provisions of this Section 4B.5 with respect to the rights of the Preferred Stock Holders after the capital reorganization
to the end that the provisions of this Section 4B.5 (including adjustment of the Conversion Price then in effect and the number
of shares issuable upon conversion of the Preferred Stock) shall be applicable after that event and be as nearly equivalent as
practicable.

 

(iii)         Other
Adjustments. The Conversion Price of Series A Stock issued by the Company to the 2005 Investors shall also be subject to other
adjustments, as follows:

 

    	 

    	 

    

 

(a)          General.

 

(x)          In
any case to which Sections 4B.5B(i) and 4B.5B(ii) hereof are not applicable, except as set forth below, where the Corporation shall
issue or sell shares of its Common Stock after the Original Issue Date for a consideration per share (after subtracting the Fair
Market Value of any securities or other assets transferred by the Corporation in units or otherwise together with such Common Stock
(“Additional Assets”)) that is less than the Conversion Price in effect at the time of issuance or sale of such
additional shares (such lower consideration per share, the “Issuance Price”), then the Conversion Price in effect
hereunder shall simultaneously with such issuance or sale be reduced to an amount equal to the Issuance Price; provided that in
the event the Issuance Price would be less than the Benchmark Price (as hereinafter defined), the Conversion Price shall be the
Benchmark Price, as further adjusted pursuant to Section 4B.5B(iii)(a)(y).

 

(y)          To
the extent that the Issuance Price shall be less than the lower of the Benchmark Price or the Conversion Price then in effect (the
“Weighted Average Price”), the Conversion Price per share in effect hereunder shall simultaneously with such
issuance or sale be further reduced to a price determined by multiplying the Weighted Average Price by the quotient of (1) an amount
equal to (x) the total number of shares of Common Stock outstanding immediately prior to such issuance or sale, assuming conversion
or exercise of all Convertible Securities and Options that are convertible or exercisable (as the case may be) at a price below
the Weighted Average Price, multiplied by the Weighted Average Price (or, in the event of further adjustments, the Conversion Price
in effect hereunder immediately prior to such issuance or sale), plus (y) the consideration, if any, received by the Corporation
upon such issuance or sale, divided by (2) the total number of shares of Common Stock outstanding immediately after issuance or
sale of such additional shares, assuming conversion or exercise of all Convertible Securities or Options that are convertible or
exercisable (as the case may be) at a price below the Weighted Average Price, multiplied by the Weighted Average Price.

 

    	 

    	 

    

 

(z)          This
Section 4B.5B(iii) shall not apply to the issuance of (i) all shares of Common Stock issued or issuable to employees, directors
or consultants pursuant to any equity compensation plan that is in effect on the date hereof, (ii) all shares of Common Stock issued
or issuable to employees, directors or consultants pursuant to any equity compensation approved by the Corporation’s Board
of Directors, including the Series A Director, (iii) all shares of Common Stock issued or issuable to bona fide leasing companies,
strategic partners, or major lenders, (iv) all shares of Common Stock issued or issuable as the purchase price in a bona fide acquisition
or merger or other strategic transaction with an unaffiliated party (including reasonable fees paid in connection therewith), or
(v) all shares of Common Stock issued upon conversion or exercise of Options or other Convertible Securities outstanding on the
date hereof.

 

(b)          Convertible
Securities.

 

(x)          In
case the Corporation shall issue or sell any securities convertible into Common Stock of the Corporation (“Convertible
Securities”) (including without limitation Additional Assets) after the Original Issue Date, there shall be determined
the price per share for which Common Stock is issuable upon the conversion or exchange thereof, such determination to be made by
dividing (1) the total amount received or receivable by the Corporation as consideration for the issue or sale of such Convertible
Securities, plus the then-current minimum aggregate amount of additional consideration, if any, payable to the Corporation upon
the conversion or exchange thereof, by (2) the maximum number of shares of Common Stock of the Corporation issuable upon the conversion
or exchange of all of such Convertible Securities for such then-current minimum aggregate amount of additional consideration.

 

    	 

    	 

    

 

(y)          If
the price per share so determined shall be less than the applicable Conversion Price, then such issue or sale shall be deemed to
be an issue or sale for cash (as of the date of issue or sale of such Convertible Securities) of such maximum number of shares
of Common Stock at the price per share so determined, provided that, if such Convertible Securities shall by their terms provide
for an increase or increases or decrease or decreases with the passage of time or otherwise, in the amount of additional consideration,
if any, to the Corporation, or in the rate of exchange, upon the conversion or exchange thereof, the adjusted Conversion Price
shall, forthwith upon any such increase or decrease becoming effective, be readjusted to reflect the same, and provided further,
that upon the expiration of such rights of conversion or exchange of such Convertible Securities, if any thereof shall not have
been exercised, the adjusted Conversion Price shall forthwith be readjusted and thereafter be the price which it would have been
had an adjustment been made on the basis that the only shares of Common Stock so issued or sold were those actually issued or sold
upon the conversion or exchange of such Convertible Securities, and that they were issued or sold for the consideration actually
received by the Corporation upon such conversion or exchange, plus the consideration, if any, actually received by the Corporation
for the issue or sale of all of such Convertible Securities.

 

(c)          Rights
and Options.

 

(x)          In
case the Corporation shall grant any rights, warrants or options to subscribe for, purchase or otherwise acquire Common Stock (collectively,
“Options”) after the Original Issue Date, there shall be determined the price per share for which Common Stock
is issuable upon the exercise of such Options, such determination to be made by dividing (1) the total amount, if any, received
or receivable by the Corporation as consideration for the granting of such Options, plus the minimum aggregate amount of additional
consideration payable to the Corporation upon the exercise of such Options, by (2) the maximum number of shares of Common Stock
of the Corporation issuable upon the exercise of such Options for such minimum aggregate amount of additional consideration.

 

    	 

    	 

    

 

(y)          If
the price per share so determined shall be less than the applicable Conversion Price, then the granting of such Options shall be
deemed to be an issue or sale for cash (as of the date of the granting of such Options) of such maximum number of shares of Common
Stock at the price per share so determined, provided that, if such Options shall by their terms provide for an increase or increases
or decrease or decreases, with the passage of time or otherwise, in the amount of additional consideration payable to the Corporation
upon the exercise thereof or in the maximum number of shares of Common Stock issuable, the adjusted Conversion Price shall, forthwith
upon any such increase or decrease becoming effective, be readjusted to reflect the same, and provided, further, that upon the
expiration of such Options, if any thereof shall not have been exercised, the adjusted Conversion Price shall forthwith be readjusted
and thereafter be the price which it would have been had an adjustment been made on the basis that the only shares of Common Stock
so issued or sold were those actually issued or sold upon the exercise of such Options and that they were issued or sold for the
consideration actually received by the Corporation for the granting of all such Options, whether or not exercised.

 

(iv)         Certain
Events. If any event occurs of the type contemplated by the provisions of this Section 4.B5 but not expressly provided for
by such provisions, then the Board of Directors of the Corporation will make an adjustment in the Conversion Price so as to protect
equitably the rights of the Series A Holders and Series B Holders.

 

    	 

    	 

    

 

		(v)	Notices, Regarding Change in Conversion Price or Otherwise.

 

(a)          Immediately
upon any adjustment of the Conversion Price with respect to the Preferred Stock, the Corporation will send written notice thereof
to all affected Preferred Stock Holders.

 

(b)          The
Corporation will send written notice to all Preferred Stock Holders at least twenty (20) days prior to the date on which the Corporation
(x) closes its books or takes a record (1) with respect to any dividend or distribution upon Common Stock, (2) with respect to
any pro rata subscription offer to holders of Common Stock, or (3) for determining rights to vote on or approve any
matter, (y) proposes to take any action on which the Preferred Stock Holders are entitled to vote pursuant to Section 4B.3 or (z)
enters into, agrees to enter into or is subject to a Material Event as described in Section 4B.4B.

 

(c)          All
notices and other communications from the Corporation to a Preferred Stock Holder shall include all material information concerning
any action, proposed action or other matter referred to in the notice or communication and shall be (x) mailed by first class registered
or certified mail, postage prepaid, (y) faxed (with confirmation) or (z) e-mailed (with receipt confirmed), at such address, fax
number or e-mail address (as the case may be) as may have been furnished to the Corporation in writing by such holder, or, until
an address, fax number or e-mail address is so furnished, to and at the address, fax number or e-mail address of the last holder
who has so furnished an address, fax number or e-mail address to the Corporation.

 

C.           Converted
Shares. Any shares of Preferred Stock which are converted pursuant to this Section 4B.5 will be canceled and will not be reissued,
sold or transferred.

 

D.           Series
B Stock. The Series B Stock is subject to exchange pursuant to the Subscription Agreement between the Company and the purchasers
thereof.

 

    	 

    	 

    

 

4B.6.      Miscellaneous.

 

A.           Registration
of Transfer. The Corporation will keep at its principal office a register for the registration of Preferred Stock. Upon the
surrender of any certificate representing Preferred Stock at such place, the Corporation will, at the request of the record holder
of such certificate, execute and deliver (at the Corporation’s expense) a new certificate or certificates in exchange therefor
representing in the aggregate the number of shares represented by the surrendered certificate. Each such new certificate will be
registered in such name and will represent such number of shares as is requested by the holder of the surrendered certificate and
will be substantially identical in form to the surrendered certificate.

 

B.           Replacement.
Upon receipt of evidence reasonably satisfactory to the Corporation (an affidavit of the registered holder will be satisfactory)
of the ownership and the loss, theft, destruction or mutilation of any certificate evidencing one or more shares of Preferred Stock,
and in the case of any such loss, theft or destruction, upon receipt of indemnity reasonably satisfactory to the Corporation, the
Corporation will (at its expense) execute and deliver in lieu of such certificate a new certificate representing the number of
shares represented by such lost, stolen, destroyed or mutilated certificate.

 

C.           Definitions.
For purposes hereof:

 

“Additional
Assets” has the meaning set forth in Section 4B.5B(iii)(a).

 

“Benchmark
Price” shall mean $7.487, subject to equitable adjustment in the event of any change in the Conversion Price pursuant
to Sections 4B.5B(i) or 4B.5B(ii).

 

“Conversion
Price” shall initially mean the purchase price paid to the Company for the issuance of the Series A Stock and the Series
B Stock (taking into account any additional shares of Series B Stock issued to the Series B Holder pursuant to its Subscription
Agreement and averaging the purchase price over all such shares), and shall be subject to adjustment from time to time in accordance
with the provisions of Section 4B.5B.

 

“Conversion
Stock” shall mean the Common Stock or other securities issuable upon conversion of the Preferred Stock as determined
in accordance with the provisions of Section 4.5.

 

    	 

    	 

    

 

“Convertible
Securities” shall have the meaning set forth in Section 4.5B(iii)(b)(x).

 

“Determination
Date” means any particular date chosen for the determination of the Fair Market Value of a share of Common Stock or Additional
Asset.

 

“Fair
Market Value” of a share of Common Stock or Additional Asset as of a Determination Date shall mean: (i), in the case
of Common Stock:

 

(a)          if
the Corporation’s Common Stock is traded on an exchange or is quoted on the National Association of Securities Dealers, Inc.
Automated Quotation (“NASDAQ”) National Market System or the NASDAQ SmallCap Market, then the closing or last sale
price, respectively, reported for the last business day immediately preceding the Determination Date;

 

(b)          if
the Common Stock is not traded on an exchange or on the NASDAQ National Market System or the NASDAQ SmallCap Market but is traded
in the over-the-counter market, then the mean of the closing bid and asked prices reported for the last business day immediately
preceding the Determination Date;

 

(c)          except
as provided in clause (d) below, if the Common Stock is not publicly traded, then as the holder and the Corporation agree or in
the absence of agreement by arbitration in accordance with the rules then standing of the American Arbitration Association, before
a single arbitrator to be chosen by the Corporation (and reasonably acceptable to the Series A Director, or, if no Series A Director
is then serving, the majority in interest of the Series A Holders) from a panel of persons qualified by education and training
to pass on the matter to be decided; and

 

    	 

    	 

    

 

(d)          if
the Determination Date is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation, dissolution
or winding up pursuant to the Corporation’s Certificate of Incorporation, as amended, then all amounts to be payable per
share to holders of the Common Stock pursuant to the Certificate of Incorporation in the event of such liquidation, dissolution
or winding up, plus all other amounts to be payable per share in respect of the Common Stock in liquidation under the Certificate
of Incorporation, assuming for the purposes of this clause (d) that all of the shares of Common Stock then issuable upon exercise
of the Warrants are outstanding at the Determination Date;

 

and (ii), in the case of Additional
Assets, the fair market value of such Additional Assets as reasonably determined by the Board of Directors of the Corporation,
without,

 

“2005
Investors” shall mean the investors or their permitted legal successors party to the Unit Subscription Agreement dated
as of January 31, 2005 between the Corporation and the investors party thereto (pursuant to which Series A Stock was issued).

 

“2007
Investors” shall mean the investors or their permitted legal successors party to the placing Letters with Ludgate Investments
Limited dated as of February 16, 2007 (pursuant to which Series A Stock was issued).

 

“Issuance
Price” shall have the meaning set forth in Section 4B.5B(iii)(a).

 

“Junior
Securities” means the Common Stock and any equity securities of any kind (but not including any debt securities convertible
into equity securities) which the Corporation or any Subsidiary at any time issues or is authorized to issue other than the Series
A Stock, unless the terms of such security explicitly state that such security shall be senior to or on a par with the Series A
Stock.

 

“Liquidation
Value” means, with respect to any share of Series A Stock or Series B Stock as of any particular date, the purchase price
paid to the Company for the issuance of the Series A Stock or Series B Stock (taking into account any additional shares of Series
B Stock issued to the Series B Holder pursuant to its Subscription Agreement and averaging the purchase price over all such shares),
subject to adjustment for any and all recapitalizations, reclassifications, stock splits, reverse stock splits, stock dividends,
subdivisions, combinations or similar events .

 

    	 

    	 

    

 

“Material
Event” shall have the meaning set forth in Section 4B.4B.

 

“Options”
shall have the meaning set forth in Section 4B.5B(iii)(c)(x).

 

“Original
Issue Date” means January 31, 2005.

 

“Person”
and “person” means an individual, a partnership, a corporation, a limited liability company, a trust, a joint
venture, an unincorporated organization and a government or any department or agency thereof.

 

“QIPO”
shall mean a firm commitment underwritten public offering of shares of Common Stock at a price per share of Common Stock in excess
of the 2007 Investors’ then-applicable Conversion Price.

 

“Required
Holders” with respect to the Series A Stock or Series B Stock shall mean the owners of a majority of the outstanding
shares of the Series A Stock or Series B Stock, respectively .

 

“Reorganization”
shall have the meaning set forth in Section 4B.4B.

 

“2005
Series A Director” shall have the meaning set forth in Section 4B.3B.

 

“2007
Series A Director” shall have the meaning set forth in Section 4B.3B.

 

“Series
A Holder” shall mean a registered holder of Series A Stock.

 

“Series
B Holder” shall mean a registered holder of Series B Stock.

 

“Series
Issuance Price” means the price paid to the Company for the issuance of the Series A Stock or Series B Stock (taking
into account any additional shares of Series B Stock issued to the Series B Holder pursuant to its Subscription Agreement and averaging
the purchase price over all such shares).

 

“Subsidiary”
means any corporation of which the shares of stock having a majority of the general voting power in electing the board of directors
are, at the time as of which any determination is being made, owned by the Corporation either directly or indirectly through Subsidiaries.

 

    	 

    	 

    

 

“Warrants”
means the Warrants exercisable for the purchase of the Common Stock, issued to the Investors pursuant to the Unit Subscription
Agreement, dated as of January 31, 2005, between the Corporation and the Investors.

 

D.           Amendment
and Waiver. No amendment, modification or waiver will be binding or effective with respect to any provision of this Article
IV adversely affecting the rights of the holders of the Series A Stock without the prior approval of the Required Holders provided
further that in the case of an amendment, modification or waiver with respect to any provision of Section 4B.5B(iii), the Required
Holders shall include a majority in interest of the 2005 Investors.

 

E.           Generally
Accepted Accounting Principles. When any accounting determination or calculation is required to be made, such determination
or calculation (unless otherwise provided) will be made in accordance with generally accepted accounting principles, consistently
applied.

 

F.           Consideration
Other Than Cash. In any case where the consideration received by this Corporation is other than cash, its value will
be deemed its fair market value as determined in good faith by the Board of Directors. Any securities shall be valued as follows:

 

(i)           Securities
not subject to investment letter or other similar restrictions on free marketability covered by (ii) below: (a) if the principal
trading market for such securities is an exchange, the average of the high reported sale prices per share of such securities for
the last five previous trading days in which a sale was reported, as officially reported on any consolidated tape, (b) if the principal
market for the Common Stock is the over-the-counter market, the average of the high reported sale prices per share on such trading
days as set forth by such market or, (c) if such securities are not quoted by such over-the-counter market, the average of the
average of the mean of the bid and asking prices per share on such trading days as set forth in the National Quotation Bureau sheet
listing such securities for such days. Notwithstanding the foregoing, if there is no reported high sale price, as the case may
be, reported on any of the ten trading days preceding the event requiring a determination of fair market value hereunder, then
the fair market value shall be the average of the high bid and asked prices for such days; and if there is no reported high bid
and asked prices, as the case may be, reported on any of the ten trading days preceding the event requiring a determination of
fair market value hereunder, then the fair market value shall be determined in good faith by resolution of the Board of Directors
of the Corporation, based on the best information available to it; provided that in the event of a dispute of the Board of Director’s
determination, the fair market value shall be determined by arbitration in accordance with the rules then standing of the American
Arbitration Association, before a single arbitrator to be chosen by the Corporation from a panel of persons qualified by education
and training to pass on the matter to be decided.

 

    	 

    	 

    

 

(ii)          The
method of valuation of securities subject to investment letter or other restrictions on free marketability (other than restrictions
arising solely by virtue of a shareholder’s status as an affiliate or former affiliate) shall be to make an appropriate discount
from the market value determined as above in clauses (i) (a), (b) or (c) to reflect the approximate fair market value thereof,
as determined in good faith by the Board of Directors of the Corporation.

 

G.           Preemptive
Rights. The Common Stockholders and the Series A Stockholders shall have such preemptive rights as are set forth in those certain
Investor Rights Agreement and Stockholders Agreement, among the Corporation and certain of its stockholders, each dated January
31, 2005, as each may be amended.

 

    	 

    	 

    

 

ARTICLE V

 

Stockholder Action

 

Stockholders of the
Corporation shall take action by (i) meetings held pursuant to this Third Amended and Restated Certificate of Incorporation and
the ByLaws or (ii) written consent in lieu a meeting pursuant to the provisions of Section 228 of the GCL. Meetings of stockholders
may be held within or without the State of Delaware, as the ByLaws may provide. Special meetings of the stockholders, for any purpose
or purposes, may be called by the Board of Directors of the Corporation or by the holders of at least 50% of the outstanding shares
of capital stock of the Corporation. The books of the Corporation may be kept (subject to any provision contained in the GCL) outside
the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the ByLaws
of the Corporation.

 

ARTICLE VI

Creditors

 

Whenever a compromise
or arrangement is proposed between the Corporation and its creditors or any class of them and/or between the Corporation and its
stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in
a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed
for the Corporation under Section 291 of the GCL or on the application of trustees in dissolution or of any receiver or receivers
appointed for the Corporation under Section 279 of the GCL order a meeting of the creditors or class of creditors, and/or of the
stockholders or class of stockholders of the Corporation, as the case may be, to be summoned in such manner as the said court directs.

 

If a majority in number
representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders
of the Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of the Corporation as
consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned
by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all
the stockholders or class of stockholders, of the Corporation, as the case may be, and also on the Corporation.

 

    	 

    	 

    

 

ARTICLE VII

Section 203 of the
GCL

 

The Corporation expressly
elects not to be governed by Section 203 of the GCL.

 

ARTICLE VIII

Management of Business
of the Corporation

 

For the management
of the business and for the conduct of the affairs of the Corporation, and in further definition, limitation and regulation of
the powers of the Corporation and of its directors and of its stockholders or any class thereof, as the case may be, it is further
provided:

 

(a) The management of
the business and the conduct of the affairs of the Corporation shall be vested in the Board of Directors, of which two members
shall be the 2005 Series A Director and the 2007 Series A Director, subject to the limitations set forth in Section 4.3B above.

 

(b) The number of directors
which shall constitute the whole Board of Directors shall be fixed by, or in the manner provided in, the Corporation’s ByLaws,
provided that they do not infringe upon the rights of the Series A Holders under Section 4.3 above. The phrase “whole Board”
and the phrase “total number of directors” shall be deemed to have the same meaning, to wit, the total number of directors
which the Corporation would have if there were no vacancies. No election of directors need be by written ballot.

 

ARTICLE IX

 

ByLaws

 

In furtherance and
not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, amend, alter or
repeal the ByLaws of the Corporation. Such power of the Board of Directors shall not divest the stockholders of the power, nor
limit their power to adopt, amend, alter or repeal the ByLaws of the Corporation.

 

    	 

    	 

    

 

ARTICLE X

Limitation of Director
Liability

 

To the fullest extent
permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors,
officers, employees and agents (and any other persons to which Delaware law permits the Corporation to provide indemnification)
through ByLaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise,
in excess of the indemnification and advancement otherwise permitted by Section 145 of the GCL, subject only to limits created
by applicable Delaware law (statutory or non-statutory).

 

To
the fullest extent permitted by applicable law, the directors of
the Corporation shall not be personally liable to the Corporation or any stockholder for monetary damages for breach of fiduciary
duty as a director, except for any matter in respect of which such director shall be liable under Section 174 of the GCL or any
amendment thereto or shall be liable by reason that, in addition to any and all other requirements for such liability, such director
(1) shall have breached the director's duty or loyalty to the Corporation or its stockholders, (2) shall have acted in a manner
involving intentional misconduct or a knowing violation of law or, in failing to act, shall have acted in a manner involving intentional
misconduct or a knowing violation of law, or (3) shall have derived an improper personal benefit. If the GCL is hereafter amended
to authorize the further elimination or limitation of the liability of a director, the liability of a director of the Corporation
shall be eliminated or limited to the fullest extent permitted by the GCL, as so amended. To the fullest extent permitted by applicable
law, each person who was or is made a party or is threatened to be made a party to or is in any way involved in any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”),
including any appeal therefrom, by reason of the fact that he or she, or a person of whom he or she is the legal representative,
is or was a director or officer of the Corporation or a direct or indirect Subsidiary, or is or was serving at the request of the
Corporation as a director or officer of another entity or enterprise, shall be indemnified and held harmless by the Corporation,
and the Corporation shall advance all expenses incurred by any such person in defense of any such proceeding prior to its final
determination, to the fullest extent authorized by the GCL. In any proceeding against the Corporation to enforce these rights,
such person shall be presumed to be entitled to indemnification and the Corporation shall have the burden of proving that such
person has not met the standards of conduct for permissible indemnification set forth in the GCL. The rights to indemnification
and advancement of expenses conferred by this Article X shall be presumed to have been relied upon by the directors and officers
of the Corporation in serving or continuing to serve the Corporation and shall be enforceable as contract rights. Said rights shall
not be exclusive of any other rights to which those seeking indemnification may otherwise be entitled. The Corporation may, upon
written demand presented by a director or officer of the Corporation or of a direct or indirect Subsidiary, or by a person serving
at the request of the Corporation as a director or officer of another entity or enterprise, enter into contracts to provide such
persons with specified rights to indemnification, which contracts may confer rights and protections to the maximum extent permitted
by the GCL, as amended and in effect from time to time. If a claim under this Article X is not paid in full by the Corporation
within sixty (60) days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring
suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall
be entitled to be paid also the expenses of prosecuting such claim. It shall be a defense to any such action (other than an action
brought to enforce the right to be advanced expenses incurred in defending any proceeding prior to its final disposition where
the required undertaking, if any, has been tendered to the Corporation) that the claimant has not met the standards of conduct
which make it permissible under the GCL for the Corporation to indemnify the claimant for the amount claimed, but the claimant
shall be presumed to be entitled to indemnification and the Corporation shall have the burden of proving that the claimant has
not met the standards of conduct for permissible indemnification set forth in the GCL.

 

    	 

    	 

    

 

If the GCL is hereafter
amended to permit the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide
prior to such amendment, the indemnification rights conferred by this Article X shall be broadened to the fullest extent permitted
by the GCL, as so amended.

 

IN WITNESS WHEREOF, the undersigned, being
the Chief Executive Officer of the Corporation, hereby certifies that the facts hereinafter stated are truly set forth, and accordingly
executes this Amended and Restated Certificate of Incorporation this __ day of March,
2009.

 

	 	 	 
	 	Dr. Harold Jacob, CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]